Previous 10 | Next 10 |
Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. The $1.4 billion landmark deal between Beijing's BeiGene and Celgene (now Bristol-Myers) is falling apart. The companies are arguing over BeiGene's C...
Marks BRUKINSA’s second approved indication in Australia, on the heels of its recent initial approval in Waldenström’s macroglobulinemia To date, BRUKINSA is approved in mantle cell lymphoma in nine countries BeiGene (NASDAQ: BGNE; HKEX: 06160), a ...
Marks BRUKINSA’s second approved indication in Australia, on the heels of its recent initial approval in Waldenström’s macroglobulinemia To date, BRUKINSA is approved in mantle cell lymphoma in nine countries BeiGene (NASDAQ: BGNE; HKEX: 06160), a ...
Represents BRUKINSA’s second recent approval in the Asia-Pacific region, following October 1 approval in Singapore for treatment of patients with mantle cell lymphoma The TGA approval is based on results from ASPEN, an Australia-inclusive head-to-head clinical trial eva...
Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...
Novartis (NYSE: NVS) announced earlier this month that the U.S. Food and Drug Administration (FDA) accepted its filing for tislelizumab to treat patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), which means that a potentia...
Insider buying decreased last week. Insiders of retail companies buying stock on the open market. Joshua Kushner and Thrive Capital continue to buy shares of OSCR. For further details see: Insider Weekends: Renewed Retail Confidence
BeiGene added to FTSE Global Equity Index Large Cap, All-World (LM), All-Cap (LMS), Total-Cap (LMSµ); as well as the Developed ESG Low Carbon Select Index and Asia ex Japan ESG Low Carbon Select Index BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology...
BeiGene (NASDAQ: BGNE) , a Chinese pharmaceutical company, saw its shares rise more than 10% in early trading on Friday. The stock, which closed at $385.24 on Thursday, opened Friday at $422 a share, climbing as high as $426.56 in mid-morning trading. The stock is up more than 55% y...
Friday's midday action saw its share of bright spots despite weakness in the overall markets. Gainers included Centene (NYSE:CNC), which climbed in the wake of takeover speculation. Meanwhile, ForgeRock (NYSE:FORG) continued its post-IPO advance, building on gains posted in its debut ses...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...